{"nct_id":"NCT01668017","title":"A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy","status":"TERMINATED","status_verified_date":"2017-07","start_date":"2012-09-30","start_date_type":"ACTUAL","primary_completion_date":"2015-05-31","primary_completion_date_type":"ACTUAL","completion_date":"2015-05-31","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["MRK"]}